This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Venous Thromboembolism (VTE)
  • /
  • Cancer Venous Thromboembolism (VTE)
Clinical trial

Cancer Venous Thromboembolism (VTE)

Read time: 1 mins
Last updated:5th Mar 2019
Status: Completed
Identifier: NCT02073682
Cancer Venous Thromboembolism (VTE)

The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.

Study Type: Interventional (Clinical Trial)
Actual Enrollment: 1046 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Actual Study Start Date: July 16, 2015
Actual Primary Completion Date: September 15, 2017
Actual Study Completion Date: September 15, 2017

- Experimental: Edoxaban group
- Active Comparator: Dalteparin group

Category Value
Study type(s) Interventional
Expected enrolment 1046
Study start date 16 July 2015
Actual study completion date 15 September 2017

View full details